Transplantation and Cellular Therapy Meetings

Olalekan Oluwole, MD, MPH, discusses the incidence and resolution of CRS and neurological events beyond two weeks following axi-cel infusion in relapsed/refractory LBCL.

Alfred L. Garfall, MD, MS, discusses data for ide-cel and lenalidomide maintenance in multiple myeloma following a suboptimal response to ASCT and lenalidomide.

Ide-cel proved feasible and effective in boosting response in patients with myeloma with suboptimal response to standard frontline therapy.

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.

Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.

Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma

Dr Dholaria discusses the phase 1 trial of P-BCMA-ALLO1, highlighting high response rates, rapid CAR T-cell expansion, and a favorable safety profile in RRMM.

Sairah Ahmed, MD, discusses evaluating NKTR-255 in combination with CD19-directed CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.

P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.

Zamto-cel produced responses and was associated with low rates of CD19 and/or CD20 antigen loss in relapsed/refractory diffuse large B-cell lymphoma.

Anakinra did not reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.

NKTR-255 combined with CD19-directed CAR T-cell therapy improved 6-month CR rates vs placebo in patients with relapsed/refractory large B-cell lymphoma.

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

Real-world ruxolitinib use in chronic GVHD was primarily in the second- or third-line, lasted for a median of 8 months, and involved dose adjustments.

Encouraging data with RFS, OS, and NRM for Orca-T was also matched in a population of patients with hematologic cancers aged 55 years and older.

Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.

In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.

Alexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.

Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.

Alice Bertaina MD, PhD, discusses T-allo10 infusion post–aβdepleted-HSCT in young patients with hematologic malignancies.